Tom 7, Nr 2 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-07-08

dostęp otwarty

Wyświetlenia strony 3122
Wyświetlenia/pobrania artykułu 2442
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologów i Położników w zakresie stosowania produktu leczniczego Xonvea® do leczenia nudności i wymiotów u kobiet w ciąży

Piotr Sieroszewski1, Hubert Huras2, Mirosław Wielgoś3, Sebastian Kwiatkowski4, Mariusz Zimmer5, Agnieszka Seremak-Mrozikiewicz6
Ginekologia i Perinatologia Praktyczna 2022;7(2):99-103.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Matthews A, Haas DM, O’Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD007575. DOI: 10.1002/14651858. CD007575.pub4. (Systematic Review).
  2. Attard CL, Kohli MA, Coleman S, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002; 186(5 Suppl Understanding): S220–S227.
  3. Piwko C, Koren G, Babashov V, et al. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013; 20: e149–160.
  4. O'Brien B, Naber S. Nausea and vomiting during pregnancy: effects on the quality of women's lives. Birth. 1992; 19(3): 138–143.
  5. Davis M. Nausea and vomiting of pregnancy: an evidence-based review. J Perinat Neonatal Nurs. 2004; 18(4): 312–328.
  6. Ozgoli G, Goli M, Simbar M. Effects of ginger capsules on pregnancy, nausea, and vomiting. J Altern Complement Med. 2009; 15(3): 243–246.
  7. Viljoen E, Visser J, Koen N, et al. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014; 13: 20.
  8. O'Donnell A, McParlin C, Robson SC, et al. Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. JAMA. 2016; 316(13): 1392–1401.
  9. Brent R. Medical, social, and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002; 186(5 Suppl Understanding): S262–S266.
  10. Koren G, Piwko C, Ahn E, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol. 2005; 25(3): 241–244.
  11. ACOG PRACTICE BULLETIN. Clinical Management Guidelines for Obstetrician–Gynecologists Number 189, January 2018 (Replaces Practice Bulletin 153, September 2015) Committee on Obstetric Practice — This Practice Bulletin was developed by the American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics in collaboration with Susan M. Ramin, MD.
  12. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995; 173(3 Pt 1): 881–884.
  13. Persaud N, Meaney C, El-Emam K, et al. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. PLoS One. 2018; 13(1): e0189978.
  14. Koren G, Clark S, Hankins GDV, et al. Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy Childbirth. 2016; 16(1): 371.
  15. Neutel CI, Johansen HL. Measuring drug effective- ness by default: the case of Bendectin. Can J Public Health. 1995; 86: 66–70.
  16. Koren G, Clark S, Hankins GDV, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010; 203(6): 571.e1–571.e7.
  17. Maltepe C, Koren G. Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int. 2013; 2013: 809787.
  18. Kutcher JS, Engle A, Firth J, et al. Bendectin and birth defects. II: Ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003; 67(2): 88–97.
  19. Bishai R, Mazzotta P, Atanackovic G, et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6). Can J Clin Pharmacol. 2000; 7(3): 138–143.
  20. Neutel I, Johansen HI. Variation in rates hospitalization for excessive vomiting in pregnancy by Bendectin/Diclectin use in Canada. Nausea and vomiting of pregnancy. State of the art. Toronto: The Motherisk Program. 2000, 54-59.
  21. Atanackovic G, Navioz Y, Moretti ME, et al. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001; 41(8): 842–845.
  22. McKeigue PM, Lamm SH, Linn S, et al. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994; 50(1): 27–37.
  23. Atanackovic G, Navioz Y, Moretti ME, et al. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001; 41(8): 842–845.
  24. Nulman I, Rovet J, Barrera M, et al. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. J Pediatr. 2009; 155(1): 45–50, 50.e1.
  25. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs. 2014; 16(3): 199–211.
  26. Fejzo MS, Magtira A, Schoenberg FP, et al. Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2015; 189: 79–84.
  27. Koren G, Clark S, Hankins GDV, et al. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy Childbirth. 2015; 15: 59.
  28. Nuangchamnong N, Niebyl J. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health. 2014; 6: 401–409.
  29. Slaughter SR, Hearns-Stokes R, van der Vlugt T, et al. FDA approval of doxylamine-pyridoxine therapy for use in pregnancy. N Engl J Med. 2014; 370(12): 1081–1083.
  30. Charakterystyka Produktu Leczniczego Xonvea®.



Ginekologia i Perinatologia Praktyczna